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Thromboxane A2 (TXA2) is a mediator implicated in pathologies such as myocardial 
infarction and atherosclerosis. The TXA2 receptor is a GPCR of which two alternative spliced 
isoforms, TPα and TPβ, have been described. In this study, we present the pharmacological 
evaluation on the individual TPα and TPβ isoforms of a series of original nitrobenzene 
sulfonylureas. We developed a model using cell lines expressing either TPα or TPβ, and 
measured the intracellular calcium mobilization triggered by TXA2 agonist. In this screening, 
several compounds displayed interesting pharmacological profiles, many exhibiting greater 
antagonistic functional activity for either TPα or TPβ. For example, JH90 was characterized 
by a selectivity TPαIC50/TPβIC50 ratio of ~10 (TPαIC50= 1590 nM ± 1320 nM; TPβIC50= 151 
nM ± 110 nM). In conclusion, we have pharmacologically defined several TP receptor 
antagonists characterized by differential activity on the TP isoforms receptors. Moreover, 
from our results, we can propose several structural moieties conferring isoform specificity. 
These agents could lead to development of pharmacological tools useful for the study of the 
specific role of TP isoform receptors. 
 
 
